

# A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)

NCT06450639

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Hoffmann-La Roche
Enrollment	50 participants

## Key Eligibility Criteria

---

### Inclusion (13)

- Signed Informed Consent Form and Signed Assent Form when appropriate
- Male at birth
- A definitive diagnosis of DMD prior to screening based on documentation of clinical findings and prior confirmatory genetic testing using a clinical diagnostic genetic test
- Age e 8 and \< 18 years at the time of signing Informed Consent Form
- Group 1 participants are required to meet the following criteria:  
... and 8 more (see full listing online)

### Exclusion (12)

- Major surgery (e.g. spinal surgery) within 3 months prior to Baseline or planned surgery or procedure that would interfere with the conduct of the study for any time during this study
- Presence of any clinically significant illness
- Has serological evidence of current, chronic, or active human immunodeficiency virus (HIV), tuberculosis (TB), hepatitis C, or hepatitis B infection
- Has a symptomatic infection (e.g. upper respiratory tract infection, pneumonia, pyelonephritis, meningitis) within 4 weeks prior to baseline
- Body weight at screening \<20 or \> 100 kg  
... and 7 more (see full listing online)

## Locations (25 total)

---

Arkansas Children's Hospital, Little Rock, Arkansas, United States  
University of California Davis Medical Center, Sacramento, California, United States  
Children's Healthcare of Atlanta Center for Advanced Pediatrics, Atlanta, Georgia, United States  
... and 22 more locations

---

<https://clinicaltrials.gov/study/NCT06450639>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.